VOLUME 31 | SUPPLEMENT 2 | MARCH 2018 MODERN PATHOLOGY 2018 ABSTRACTS GYNECOLOGIC AND OBSTETRIC PATHOLOGY (1127-1316) 107TH ANNUAL MEETING GEARED TO LEARN Vancouver Convention Centre MARCH 17-23, 2018 Vancouver, BC, Canada PLATFORM & 2018 ABSTRACTS POSTER PRESENTATIONS EDUCATION COMMITTEE Jason L. Hornick, Chair Amy Chadburn Rhonda Yantiss, Chair, Abstract Review Board Ashley M. Cimino-Mathews and Assignment Committee James R. Cook Laura W. Lamps, Chair, CME Subcommittee Carol F. Farver Steven D. Billings, Chair, Interactive Microscopy Meera R. Hameed Shree G. Sharma, Chair, Informatics Subcommittee Michelle S. Hirsch Raja R. Seethala, Short Course Coordinator Anna Marie Mulligan Ilan Weinreb, Chair, Subcommittee for Rish Pai Unique Live Course Offerings Vinita Parkash David B. Kaminsky, Executive Vice President Anil Parwani (Ex-Officio) Deepa Patil Aleodor (Doru) Andea Lakshmi Priya Kunju Zubair Baloch John D. Reith Olca Basturk Raja R. Seethala Gregory R. Bean, Pathologist-in-Training Kwun Wah Wen, Pathologist-in-Training Daniel J. Brat ABSTRACT REVIEW BOARD Narasimhan Agaram Mamta Gupta David Meredith Souzan Sanati Christina Arnold Omar Habeeb Dylan Miller Sandro Santagata Dan Berney Marc Halushka Roberto Miranda Anjali Saqi Ritu Bhalla Krisztina Hanley Elizabeth Morgan Frank Schneider Parul Bhargava Douglas Hartman Juan-Miguel Mosquera Michael Seidman Justin Bishop Yael Heher Atis Muehlenbachs Shree Sharma Jennifer Black Walter Henricks Raouf Nakhleh Jeanne Shen Thomas Brenn John Higgins Ericka Olgaard Steven Shen Fadi Brimo Jason Hornick Horatiu Olteanu Jiaqi Shi Natalia Buza Mojgan Hosseini Kay Park Wun-Ju Shieh Yingbei Chen David Hwang Rajiv Patel Konstantin Shilo Benjamin Chen Michael Idowu Yan Peng Steven Smith Rebecca Chernock Peter Illei David Pisapia Lauren Smith Andres Chiesa-Vottero Kristin Jensen Jenny Pogoriler Aliyah Sohani James Conner Vickie Jo Alexi Polydorides Heather Stevenson-Lerner Claudiu Cotta Kirk Jones Sonam Prakash Khin Thway Tim D’Alfonso Chia-Sui Kao Manju Prasad Evi Vakiani Leona Doyle Ashraf Khan Bobbi Pritt Sonal Varma Daniel Dye Michael Kluk Peter Pytel Marina Vivero Andrew Evans Kristine Konopka Charles Quick Yihong Wang Alton Farris Gregor Krings Joseph Rabban Christopher Weber Dennis Firchau Asangi Kumarapeli Raga Ramachandran Olga Weinberg Ann Folkins Frank Kuo Preetha Ramalingam Astrid Weins Karen Fritchie Alvaro Laga Priya Rao Maria Westerhoff Karuna Garg Robin LeGallo Vijaya Reddy Sean Williamson James Gill Melinda Lerwill Robyn Reed Laura Wood Anthony Gill Rebecca Levy Michelle Reid Wei Xin Ryan Gill Zaibo Li Natasha Rekhtman Mina Xu Tamara Giorgadze Yen-Chun Liu Michael Rivera Rhonda Yantiss Raul Gonzalez Tamara Lotan Mike Roh Akihiko Yoshida Anuradha Gopalan Joe Maleszewski Marianna Ruzinova Xuefeng Zhang Jennifer Gordetsky Adrian Marino-Enriquez Peter Sadow Debra Zynger Ilyssa Gordon Jonathan Marotti Safia Salaria Alejandro Gru Jerri McLemore Steven Salvatore To cite abstracts in this publication, please use the following format: Author A, Author B, Author C, et al. Abstract title (abs#). Modern Pathology 2018; 31 (suppl 2): page# GYNECOLOGIC AND OBSTETRIC PATHOLOGY consistent as “near perfect” level of agreement. Results: Pts’ ages ranged from 27-85(median 60)yrs. All pts underwent definite surgical treatment. Bx included 65% endometrioid carcinoma(EEC), 17% CAH, 15% serous carcinoma(SC), 1.5% clear 1127 Does Loss of Heterozygosity Impact Prognosis in cell and 1.5% mixed carcinoma. High level of concordance was Uterine Serous Carcinoma? achieved for MMR-loss; MLH1[1.0(0.0-7.74)], PMS2[0.91(0.61-7.08)], MSH2[1.0(0.0-7.74)] and MSH6[0.83(0.79-6.49)], MSI high[0.91(0.63- Eman Abdulfatah1, Sudeshna Bandyopadhyay2, Resha Shrestha3, 6.86)], P53 wild[1.0(0.0-7.74)] and abn[1.0(0.0-7.74)] types. In contrast, MHD Fayez Daaboul4, Andrea Loehr5, Andy Simmons6, Robert Morris7, grade and histotype showed only moderate levels of agreement. Rouba Ali-Fehmi2. 1Wayne State University, Detroit, MI, 2Wayne Highest level of discrepancy in morphology was between SC and State University, Detroit, MI, 3Wayne State University, Detroit, MI, FIGO grade 3 EEC. POLE gene mutation was detected in 2 pts (3.5% of 4Wayne State University, 5Clovis Oncology, San Francisco, CA, 6Clovis entire cohort and 14% of FIGO grade 3 EEC). For both pts, mutations Oncology, 7Karmanos Cancer Institute were detected only in HS. When comparing CAH with subsequent Background: While uterine serous carcinomas (USCs) are HS tumor, the profile was identical to that of EC. morphologically and immunophenotypically indistinguishable from Conclusions: In our cohort of EC, high level of concordance was their ovarian counterparts, questions remain on whether these achieved between Bx and HS for IHC and molecular profile, superior tumors share similar molecular profile and therefore could benefit to that of grade and histotype, providing earlier and more reliable from similar therapies. Somatic and germline defects in genes of prognostic information to inform management. the homologous recombinant(HR) pathway(BRCA1, BRCA2 and others) have been implicated in ovarian cancer predisposition and are associated with high sensitivity to platinum-based and targeted therapies(PARP inhibitors). HR deficiency impairs normal DNA repair 1129 Micropapillary Carcinoma of the Uterine Cervix. A resulting in loss or duplication of chromosomal regions, termed Clinicopathologic Study of 25 Cases genomic loss of heterozygosity(LOH). Whether this phenomenon Isabel Alvarado-Cabrero1, Maria Delia Perez Montiel2, Rafael Estevez- applies to USCs is yet to be determined. In this study, we analyzed Castro3, Jessica Gomez4, Javier Canedo-Matute5, Vilma M Rivas- genome-wide LOH in USCs and correlated its extent with Lemus6, Raquel Valencia-Cedillo7. 1Mexican Oncology Hospital, clinicopathological parameters and survival outcomes. Mexico, 2Instituto Nacional de Cancerologia, Mexico City, 3Laboratorio Design: 69 platinum treated USC patients diagnosed between 1998- de Patología Dra. Rosario Castro, Santiago, República Dominicana, 2015 were included. DNA was isolated from FFPE and LOH analysis 4Mexico, 5Laboratorio de Patología y Citología (LAPACI) Medellín, was performed querying over 220,000 SNPS using the Affymetrix Colombia, 6Hospital San Juan de Dios de Santa Ana, El Salvador, OncoScan. Selecting the top quartile of LOH distribution as a cut point 7Hospital de Oncología, Mexico to separate patients into LOH “high” and LOH “low” groups, data was Background: Micropapillary carcinoma is a rare variant of analyzed using KM survival analyses. endocervical adenocarcinoma. All nine cases reported in the Results: Patients’ ages ranged from 45 - 89(median 68) yrs. literature have been associated with pelvic or para-aortic lymph node Stage distribution included: 11.5% I, 1.5% II, 62% III and 25% IV. metastases. The behavior of this rare malignancy could be different Lymphadenectomy was performed in 74% and omentectomy in 62% of from that of conventional endocervical adenocarcinoma. Hence, there patients. 80% of patients received adjuvant radiotherapy. Median LOH is a need to highlight this histopathological entity. was 1.4% (range 0-30.1%) and the top quartile threshold was 9.9%. 52 The goal of this study is to analize the clinical, histopathologic findings tumors showed LOH lower than the top quartile. In the top quartile of and prognosis of micropapillary endocervical adenocarcinoma LOH, tumors were more common in African Americans(83% vs 56%), advanced stage(100% vs 82%) and more commonly associated with Design: This was a retrospective multi-institutional study of patients outer half MI(76.5% vs 47%) and LVI(88% vs 65%) when compared who presented with endocervical adenocarcinoma (EAC) during the to tumors with LOH lower than the top quartile. In general, LOH period from January 1, 2000 to December 31, 2016. The study was did not significantly correlate with age(p=0.41), race(p=0.43), restricted to cases in which the micropapillary component constituied tumor size(p=0.72), stage(p=0.36), MI(p=0.52), LVI(p=0.40), LN at least 95% of the tumor. Clinical data, including postoperative follow- metastases(p=0.43), or recurrence(p=0.34). KM analysis showed no up, were obtained from the medical records. survival benefit nor prolonged DFI for platinum treated patients with Results: Twenty-five cases of endocervical adenocarcinoma (EAC) LOH in the top quartile compared to LOH lower than that. containing a micropapillary component (MPC) are present. The Conclusions: In our cohort of USCs, median LOH was 1.4%, with patients´ mean age was 64 years (range, 49-84 years). Nineteen 25% of tumors showing genomic LOH higher than 9.9%. In contrast patients had pelvic or para-aortic lymph node metastases, each with a to their ovarian counterparts, a high degree of genomic LOH does predominant (> or: 50%) MPC in the metastases; local recurrence was not correlate with survival benefit for platinum treated USC patients, documented in 8 cases. Vascular-lymphatic invasion was consistently suggesting that these tumors may have distinct biology and genomic present. The cytologic features of the MPC were those of grade 3 EAC profile. in 16 cases. A concurrent endocervical adenocarcinoma was identified in 12 cases. A total of 7(28%) patients were stage I, 11(44%) were stage II and 7 (28%) stage III. The mean tumor size was 3.61 cm (2-5cm). 1128 Molecular Classification of Endometrial Carcinoma Depth of invasion ranged from 10 to 34mm (mean: 11.3mm). Tumor Applied to Endometrial Biopsy Specimens: involvement in